FRANKENFIELD CHRISTOPHER JAMES (Chief Operating Officer) sold 35.9% of their position (6.95K shares) of XILIO THERAPEUTICS, INC. on the open market
Open‑market sale worth $6.8K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/3/2025ACC: 0001415889-25-000407
Officer· Chief Operating Officer
Since Aug 2023
+244.05K
Net shares
Net buyer
$6.8K
Total sold
1
Open market trades
0B · 1S
4
Total transactions
270.38K acquired · 26.33K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+19.38K
Price / share
—
Trade value
—
% of position
New position
1/1/2025
0.00→19.38K
Common stock
Direct
Shares
−6.95K
Price / share
$0.98
Trade value
$6.84K
% of position
35.9%
1/2/2025
19.38K→12.42K
Total
Net shares
+12.42K
Net value
-$6.84K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/1/2025 | M · Option Exercise | +19.38K | — | — | New position | 0.00 | 19.38K |
| Common stock Direct | 1/2/2025 | S · Sale | −6.95K | $0.98 | $6.84K | 35.9% | 19.38K | 12.42K |
| Total | +12.42K | -$6.84K | ||||||
Derivative Transactions2
Restricted Stock Units
Direct
Converts to
Common Stock
19.38K shares
Shares
−19.38K
Strike price
Held after
58.13K
Exercisable
—
1/1/2025
Stock Option (right to buy)
Direct
Converts to
Common Stock
251K shares
Shares
+251K
Strike price
0.955
Held after
251K
Exercisable
—
1/1/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock19.38K shares | 1/1/2025 | M · Option Exercise | −19.38K | — | 58.13K | |
| Stock Option (right to buy) Direct | Common Stock251K shares | 1/1/2025 | A · Award | +251K | 0.955 | — | 251K |